<div id="readability-page-1"><p><span>Amarin (NASDAQ:AMRN - Get Free Report)</span> was downgraded by analysts at Zacks Research from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($2.93) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($2.71) EPS, Q2 2026 earnings at ($2.55) EPS, Q3 2026 earnings at ($4.22) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($17.05) EPS, Q1 2027 earnings at ($2.77) EPS, Q2 2027 earnings at ($2.77) EPS, Q3 2027 earnings at ($3.33) EPS, Q4 2027 earnings at ($6.46) EPS and FY2027 earnings at ($15.33) EPS.</p><ul><li>3 Biotech Stocks Gaining Momentum</li></ul><p>A number of other equities research analysts have also recently issued reports on the company. Wall Street Zen cut Amarin from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, November 28th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Amarin in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Sell rating,  Based on data from MarketBeat, the company currently has a consensus rating of &#34;Strong Sell&#34; and an average target price of $12.00.</p><p><b>View Our Latest Stock Report on AMRN</b></p><h2>Amarin Price Performance</h2><ul><li>Are Ocugen or Amarin Good Penny Stocks to Buy? </li></ul><p>Amarin stock opened at $15.07 on Tuesday. The company has a market cap of $313.31 million, a price-to-earnings ratio of -6.05 and a beta of 0.72. The firm has a 50-day moving average of $14.91 and a 200-day moving average of $15.80. Amarin has a one year low of $7.08 and a one year high of $20.90. </p><h2>Institutional Trading of Amarin</h2><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Waterfront Wealth Inc. grew its position in shares of  Amarin by 82.8% during the 4th quarter. Waterfront Wealth Inc. now owns 142,540 shares of the biopharmaceutical company's stock worth $1,990,000 after purchasing an additional 64,580 shares in the last quarter.  JPMorgan Chase &amp; Co. raised its position in shares of  Amarin by 534.2% in the third quarter. JPMorgan Chase &amp; Co. now owns 21,754 shares of the biopharmaceutical company's stock valued at $356,000 after buying an additional 18,324 shares in the last quarter.  Northwestern Mutual Wealth Management Co. boosted its stake in shares of  Amarin by 1,816.7% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 5,450 shares during the period.  Millennium Management LLC grew its position in  Amarin by 192.6% during the third quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company's stock worth $2,169,000 after buying an additional 87,147 shares in the last quarter.  Finally, Ameriprise Financial Inc. increased its stake in  Amarin by 13.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company's stock worth $285,000 after acquiring an additional 2,008 shares during the period. Institutional investors and hedge funds own  22.25% of the company's stock. </p><h2>Amarin Company Profile</h2> (Get Free Report)<ul><li>Does Amarin Deserve a Spot in Your Portfolio after Earnings ?</li></ul><p>Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin's primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.  </p><p>The company's flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Amarin</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Do not delete, read immediately</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amarin Right Now?</h2><p>Before you consider Amarin, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.</p><p>While Amarin currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMRN

<p>Zacks Research downgraded shares of Amarin from a "hold" rating to a "strong sell" rating in a research note on Tuesday.</p>

Amarin (NASDAQ:AMRN) Stock Rating Lowered by Zacks Research